Pfizer Works With Roche To Increase Diagnostic Services For Xalkori Launch In China’s Self-Pay Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite no reimbursement in sight, Pfizer still sees a huge potential for targeted lung cancer drug Xalkori in China. To quickly ramp up eligible patients, Pfizer is working with Roche to offer discounted diagnostic services to identify best responders.